Trial Profile
A Phase 1b/2a Open-label, Multi-center Study to Assess the Safety, Efficacy and Pharmacokinetics of Intrapatient Dose-adjusted Brequinar and Inhibition of Dihydroorotate Dehydrogenase (DHODH) in Adult Subjects With AML
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Brequinar (Primary) ; Ribavirin (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; T-cell leukaemia
- Focus Adverse reactions
- Sponsors Clear Creek Bio
- 02 Aug 2021 Status changed from active, no longer recruiting to completed.
- 19 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2020 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.